Markets:

Overview

News

Currencies

International

Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Revance Shares Plunge On FDA Response Letter For Frown Line Candidate ↗

October 18, 2021

The FDA has issued a Complete Response Letter (CRL) regarding Revance Therapeutics Inc's (NASDAQ: RVNC) marketing application for DaxibotulinumtoxinA for...

Via Benzinga

50 Biggest Movers From Yesterday ↗

October 14, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

October 13, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Why Revance Therapeutics Stock Is Bolting Higher Today ↗

October 13, 2021

Management's response to a publicly disclosed regulatory form has investors doing a U-turn.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 13, 2021

Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

October 13, 2021

MKM Partners raised the price target on Continental Resources, Inc. (NYSE:

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗

October 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...

Via Benzinga

Earnings Scheduled For May 10, 2021 ↗

May 10, 2021

Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...

Via Benzinga

45 Biggest Movers From Yesterday ↗

October 13, 2021

Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on...

Via Benzinga

How Bad Are Revance Therapeutics's Earnings? | Return On Capital Employed ↗

September 03, 2021

Revance Therapeutics (NASDAQ:RVNC) brought in sales totaling $18.80 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 0.46%, resulting in a...

Via Benzinga

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...

Via Talk Markets

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...

Via Benzinga

Looking Into Revance Therapeutics's Return On Capital Employed ↗

June 24, 2021

Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. Revance...

Via Benzinga

Looking Into Revance Therapeutics's Return On Capital Employed ↗

June 08, 2021

Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. In Q4, Revance...

Via Benzinga

Recap: Revance Therapeutics Q1 Earnings ↗

May 10, 2021

Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the...

Via Benzinga

Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal ↗

May 01, 2021

CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million...

Via Talk Markets

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight ↗

April 10, 2021

Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

Headline News about Revance Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today